AIM ImmunoTech Announces Pricing of $2.0 Million Registered Direct Offering

by Barry101 | May 31, 2024 | Press Release

OCALA, Fla., May 31, 2024 — AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today announced that it has entered into a securities purchase agreement with a single institutional investor to purchase 5,640,958 shares of...

AIM ImmunoTech to Participate in Two Upcoming Investor Conferences

by Barry101 | May 20, 2024 | Press Release

OCALA, Fla., May 20, 2024 — AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today announced that AIM Chief Executive Officer Thomas K. Equels will participate in two upcoming investor conferences. Details for the...

AIM ImmunoTech Reports First Quarter 2024 Financial Results and Provides Corporate Update

by Barry101 | May 16, 2024 | Press Release

Continued execution across Ampligen® clinical development programs and growing body of positive data in multiple high-value indications Company to host conference call and webcast today, May 16, at 8:30 AM ET OCALA, Fla., May 16, 2024 — AIM ImmunoTech Inc....

AIM ImmunoTech to Discuss First Quarter 2024 Financial Results on May 16, 2024, and Host Conference Call and Webcast

by Barry101 | May 9, 2024 | Press Release

OCALA, Fla., May 09, 2024 — AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) announced today that management will host a conference call and webcast to discuss the Company’s Q1 2024 operational and financial results...

AIM ImmunoTech Completes cGMP Manufacturing of Clinical Vials of Ampligen®

by Barry101 | May 6, 2024 | Press Release

OCALA, Fla., May 06, 2024 — AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today announced the successfully completion of cGMP manufacturing of 9,042 clinical vials of Ampligen® (rintatolimod), AIM’s dsRNA...